Zevra Therapeutics (NASDAQ:ZVRA) Releases Earnings Results, Misses Expectations By $0.28 EPS

Zevra Therapeutics (NASDAQ:ZVRA) announced its quarterly earnings data on Tuesday. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28), Zacks reports. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The firm had revenue of $12.00 million during the quarter, compared to analysts’ expectations of $8.93 million.

Zevra Therapeutics Price Performance

Shares of Zevra Therapeutics stock opened at $8.07 on Wednesday. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics has a 12 month low of $4.20 and a 12 month high of $9.76. The stock has a 50 day moving average of $7.96 and a 200 day moving average of $8.14. The firm has a market cap of $430.74 million, a PE ratio of -4.10 and a beta of 1.98.

Wall Street Analyst Weigh In

ZVRA has been the subject of a number of analyst reports. Cantor Fitzgerald upgraded Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 29th. Canaccord Genuity Group cut their target price on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. Finally, Guggenheim set a $21.00 price target on Zevra Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, February 4th. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $21.71.

Insiders Place Their Bets

In related news, CEO Neil F. Mcfarlane sold 61,273 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $481,605.78. Following the sale, the chief executive officer now owns 222,060 shares in the company, valued at approximately $1,745,391.60. The trade was a 21.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO R. Laduane Clifton sold 11,000 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $86,460.00. Following the sale, the chief financial officer now directly owns 51,361 shares in the company, valued at approximately $403,697.46. The trade was a 17.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 85,773 shares of company stock valued at $674,176 in the last quarter. 2.40% of the stock is currently owned by insiders.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.